Amgen Legal Victory Overturns Patent Ruling Boosts Stock Ranks 177th in Trading Volume

Amgen (AMGN.O) rose 0.33% on Thursday with a trading volume of $560 million, ranking 177th in the stock market. The biopharmaceutical giant secured a legal victory in a Delaware federal court, which invalidated two patents held by Germany-based Lindis Biotech. This decision overturned a $50.3 million jury verdict from December 2024, which had found Amgen liable for patent infringement related to its leukemia drug Blincyto.

The ruling by U.S. District Judge Gregory Williams cited "inequitable conduct" by the patent inventor during the application process at the U.S. Patent and Trademark Office. The invalidated patents pertained to technology aimed at reducing side effects from antibody-based cancer treatments. Amgen’s legal team argued the patents were unenforceable due to false information submitted in the application, a claim the judge accepted in a sealed opinion. The company reported $800 million in U.S. sales of Blincyto last year, highlighting its commercial significance.

Lindis Biotech had sued Amgen in 2022, alleging infringement of its intellectual property. The Delaware jury had previously deemed the infringement "willful," which could have tripled the damages. However, the latest decision eliminates this financial exposure and strengthens Amgen’s market position in the competitive oncology sector. Legal representatives for both parties have not publicly commented on the outcome.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.